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Once again, the new SARS-CoV-2 reminds us about the potential of infectious pathogens to fiercely
spread worldwide and puts our well-being in danger. With respect to its pathogenicity, one may be
reminded of two simple principles that underlie our constant fight with viruses of our surrounding,
the “numbers game” and “immune geography” (Zinkernagel et al., 1985). These conceptual terms
refer to the kinetics of virus growth and immune reactions, and the spatial organization of immune
responses in relation to viral entry sites and tissue tropismwhich determines cytokine gradients and
immune cell homing patterns across tissues, respectively. Jointly, both concepts provide a rationale
for a dynamic view on the balance between virus expansion and development of antiviral immune
responses that will ultimately help to understand virus pathogenicity and how to gain immune
control (Figure 1A).
Coronaviruses are a family of enveloped plus-strand RNA viruses that infect mammals and
birds. In humans, there are four endemic, usually mildly pathogenic viruses 229E, OC43, NL63 and
HKU1, and the newly emerged viruses SARS-CoV, MERS-CoV, and SARS-CoV-2 that cause lethal
infections in around 10, 30, and 1% of cases, respectively (Gaunt et al., 2010; Raoult et al., 2020).
All these viruses can be transmitted by aerosols and infect the upper respiratory tract and the lung.
However, since human infections only allow for very limited experimental manipulations, much
of our fundamental knowledge of virus infections are derived from animal studies. To understand
the containment of the initial virus spread, which subsequently determines virus pathogenicity,
the murine coronavirus (M-CoV, also known as mouse hepatitis virus, MHV) model system is
most instructive. M-CoV is a rapidly replicating, highly cytopathic virus that leads to severe
inflammation in several organs and can disseminate via the bloodstream. In particular, the liver,
a peripheral organ and the spleen, a secondary lymphoid organ, are the major target organs of this
virus, and hematopoietic cell-derived type I interferon (IFN) primarily controls viral replication
and virus-induced liver disease. Three clinical outcomes are observable that depend on the balance
of infection spreading and the innate immune response (Figure 1B). With an optimal innate
response, the infection is well controlled and generates onlymild symptoms, whereas, a delayed and
weak innate response results in severe infection spread and fatal outcome. Between these extremes,
tissue damage of various severity is observed but the host ultimately survives.
How can this qualitative description of virus-induced pathogenicity be transformed into a more
quantitative characterization of host protection and its limits? A systems biology-based analysis
combining experimental data of murine coronavirus infection and mathematical modeling has
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FIGURE 1 | Kinetic view on CoV pathogenesis. (A) The numbers game between virus growth and immune response determines virus infection outcomes. (B) Early
innate immune responses determine viral pathogenesis. (C) Degree of robustness of protection against a faster replicating M-CoV strain in relation to its preferential
site of replication, i.e., a peripheral organ (liver) vs. a lymphoid organ (spleen). Virus is represented as a solid line while broken lines characterize the immune response.
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shown that the robustness of innate immune response-mediated
protection from severe disease is rather limited (summarized
in Figure 1C) when putative CoV variants exhibiting enhanced
tropism and replication in peripheral organ cells like hepatocytes
rather than lymphoid tissue cells were considered (Bocharov
et al., 2010, 2018). For example, a 20% increase of the exponential
growth rate of M-CoV A59 strain (estimated to be 0.78 infectious
particles/ml/h) leads to a severe infection as manifested by a
substantial rise of liver enzyme values in serum (i.e., alanine
transferase (ALT) level rise to 1,000 IU/L) within 2 days.
On the contrary, a substantial rise of up to 30-fold of the
virus replication rate in macrophages of the spleen (estimated
to be about 37 infectious particles/cell/h for M-CoV A59 in
C57BL/6 mice) is efficiently disarmed by plasmacytoid dendritic
cell-produced type I IFN, thus providing robust protection
against severe disease (Bocharov et al., 2010). In general terms,
differences of innate immune responses in lymphoid tissues
such as the spleen or lymph nodes in which local levels of
type I IFN increase sharply when viruses replicate, provide a
swift host protection, whereas virus replication in non-lymphoid
tissue like liver or lung generate slower type I IFN increases
reaching lower levels and thus being less efficient in restriction of
viral replication.
How do the above numbers relate to the rate of infection
spreading in the case of SARS-CoVs? The available experimental
data on the virus growth kinetics in Vero E6 cells in vitro provide
estimates of the exponential growth rates of SARS-CoV-1 to be
about 0.74 RNA/ml/h (Keyaerts et al., 2005) and 0.84 infectious
particles/ml/h. Recent data for SARS-CoV-2 provide a similar
growth rate (Lokugamage et al., 2020). The remarkable similarity
of the values and the preferential tropism of the SARS-CoV
viruses to cells of the upper respiratory tract and lungs would
suggest that the robustness of protection against SARS-CoV
spreading in this peripheral organ by the innate IFN response
is limited. Thus, it is conceivable that SARS-CoV infections are
operating close to the edge of the protective capacity of the
host’s type I IFN system. Consequently, changes in type I IFN-
sensitivity of the viruses, their IFN-suppressive properties as
well as changes in type I IFN-responsiveness of infected hosts
i.e., due to genetic polymorphisms, immunosuppressive drugs or
aging might all have relevant clinical consequences. Indeed, it
has already been speculated for SARS- and MERS-CoVs that a
delay in virus restriction by the early type I IFN response may
lead to exaggerated inflammatory, life-threatening conditions
later during the infection course (Prompetchara et al., 2020).
With respect to SARS-CoV-2 infections, recent data suggest that
an impaired systemic type I IFN response correlates with the
severity of COVID-19 (Arunachalam et al., 2020). Furthermore,
since aging affects multiple layers of the immune control of
viruses including an altered innate response and correlates to
COVID-19 severity (Akbar and Gilroy, 2020)(https://ebrary.net/
30820/health/pdcs), further longitudinal studies in humans of
this complex relationship are warranted.
Clearly, the degree of fragility, i.e., the sensitivity of
CoV-induced infection severity to viral infection dose and growth
rate increases in humans, and the limits of protection provided
by the type I IFN system that acts at the front line of the virus-
host interaction deserve further quantitative analyses. The higher
type I IFN sensitivity of SARS-CoV-2 compared to SARS-CoV
indicates that a type I IFN treatment of a virus-exposed individual
would be an efficient early therapeutic modality that could
prevent subsequent severe disease. This view is now supported
by latest clinical data that show favorable clinical responses and
reduced mortality after early type I IFN administration (Wang
et al., 2020). Furthermore, given the large reservoir of CoVs in
bats (Menachery et al., 2015), testing their properties with respect
to growth rates, IFN-sensitivity and IFN-suppressive capacity
might help to be prepared for the next pandemic to come. It is
only a question of time.
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